Arvinas Inc. (ARVN)
7.74
0.00 (0.00%)
Upcoming Events
Latest Headlines
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 4, 2026 8:00 AM - StreetInsider
Form 8-K ARVINAS, INC. For: Jun 02
June 2, 2026 4:40 PM - SEC Filing
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026 4:01 PM - StreetInsider
Form 4 ARVINAS, INC. For: May 21 Filed by: Teel Randy
May 22, 2026 4:16 PM - SEC Filing
Form 144 ARVINAS, INC. Filed by: Teel Randy
May 20, 2026 5:34 PM - SEC Filing
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026 10:30 AM - Globe NewsWire
Form 4 ARVINAS, INC. For: May 11 Filed by: Saik Andrew
May 13, 2026 4:20 PM - SEC Filing
Form 4 ARVINAS, INC. For: May 11 Filed by: Loomis David K
May 13, 2026 4:18 PM - SEC Filing
Form 4 ARVINAS, INC. For: May 11 Filed by: Cacace Angela M
May 13, 2026 4:17 PM - SEC Filing
Form 4 ARVINAS, INC. For: May 11 Filed by: Berkowitz Noah
May 13, 2026 4:16 PM - SEC Filing
Form 4 ARVINAS, INC. For: May 11 Filed by: Teel Randy
May 13, 2026 4:16 PM - SEC Filing
Arvinas Inc. (ARVN) PT Raised to $16 at BofA Securities
May 13, 2026 2:53 PM - StreetInsider
Arvinas Inc. (ARVN) PT Raised to $18 at BTIG
May 13, 2026 6:04 AM - StreetInsider
Arvinas Inc. (ARVN) PT Raised to $20 at Barclays
May 13, 2026 4:22 AM - StreetInsider
Form 8-K ARVINAS, INC. For: May 12
May 12, 2026 7:16 AM - SEC Filing
Form 8-K ARVINAS, INC. For: May 11
May 12, 2026 7:15 AM - SEC Filing
Arvinas, Inc. (ARVN) Tops Q1 EPS by 3c
May 12, 2026 7:07 AM - StreetInsider
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026 7:05 AM - Globe NewsWire
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026 7:01 AM - StreetInsider
Arvinas and Pfizer sell VEPPANU rights to Rigel for $85 million upfront
May 12, 2026 7:01 AM - StreetInsider
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026 7:00 AM - Globe NewsWire
Form 10-Q ARVINAS, INC. For: Mar 31
May 11, 2026 5:19 PM - SEC Filing
Form 144 ARVINAS, INC. Filed by: Saik Andrew
May 8, 2026 6:06 PM - SEC Filing
Form 144 ARVINAS, INC. Filed by: Cacace Angela M
May 8, 2026 6:06 PM - SEC Filing
Form 144 ARVINAS, INC. Filed by: Berkowitz Noah
May 8, 2026 6:06 PM - SEC Filing
Form 144 ARVINAS, INC. Filed by: Teel Randy
May 8, 2026 6:05 PM - SEC Filing
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026 7:00 AM - Globe NewsWire
Arvinas Inc. (ARVN) PT Raised to $24 at Citi
May 4, 2026 5:13 AM - StreetInsider
BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)
May 1, 2026 3:39 PM - StreetInsider
Arvinas shares gain as FDA approves breast cancer drug Veppanu
May 1, 2026 1:12 PM - StreetInsider
Form 8-K ARVINAS, INC. For: May 01
May 1, 2026 12:58 PM - SEC Filing
FDA approves first PROTAC therapy VEPPANU for breast cancer
May 1, 2026 12:43 PM - StreetInsider
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 1, 2026 12:43 PM - Globe NewsWire
Form ARS ARVINAS, INC. For: Dec 31
April 29, 2026 9:47 AM - SEC Filing
Form DEFA14A ARVINAS, INC.
April 29, 2026 9:32 AM - SEC Filing
Form DEF 14A ARVINAS, INC. For: Jun 24
April 29, 2026 9:32 AM - SEC Filing
Form SCHEDULE 13G ARVINAS, INC. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 28, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A ARVINAS, INC. Filed by: VANGUARD GROUP INC
March 26, 2026 3:45 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
March 20, 2026 6:47 AM - StreetInsider
Form 4 ARVINAS, INC. For: Mar 18 Filed by: Berkowitz Noah
March 19, 2026 8:02 PM - SEC Filing
Arvinas Inc. (ARVN) PT Raised to $16 at BTIG
March 18, 2026 3:48 PM - StreetInsider
Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data
March 18, 2026 11:18 AM - StreetInsider
Form 8-K ARVINAS, INC. For: Mar 18
March 18, 2026 7:07 AM - SEC Filing
Arvinas reports positive phase 1 data for Parkinson's drug ARV-102
March 18, 2026 7:00 AM - StreetInsider
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026 7:00 AM - StreetInsider
Form 144 ARVINAS, INC. Filed by: Berkowitz Noah
March 17, 2026 7:25 PM - SEC Filing
Form 4/A ARVINAS, INC. For: Feb 26 Filed by: Teel Randy
March 12, 2026 5:41 PM - SEC Filing
Arvinas to present phase 1 data for ARV-102 Parkinson's drug at conference
March 11, 2026 7:00 AM - StreetInsider
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorder
March 11, 2026 7:00 AM - StreetInsider
Form 4 ARVINAS, INC. For: Mar 06 Filed by: Morrison Briggs
March 9, 2026 4:05 PM - SEC Filing
Full Article List
